NASACORT ALLERGY 24 HOUR Drug Patent Profile

When do Nasacort Allergy 24 Hour patents expire, and when can generic versions of Nasacort Allergy 24 Hour launch?

Nasacort Allergy 24 Hour is a drug marketed by Chattem Sanofi and is included in one NDA.

The generic ingredient in NASACORT ALLERGY 24 HOUR is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nasacort Allergy 24 Hour

A generic version of NASACORT ALLERGY 24 HOUR was approved as triamcinolone acetonide by TARO on October 1^st, 1986.

Summary for NASACORT ALLERGY 24 HOUR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	82
Clinical Trials:	8
Patent Applications:	4,284
DailyMed Link:	NASACORT ALLERGY 24 HOUR at DailyMed

Recent Clinical Trials for NASACORT ALLERGY 24 HOUR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gail Gauvreau	N/A
Stanford University	Phase 4
Sanofi	Phase 4

See all NASACORT ALLERGY 24 HOUR clinical trials

Pharmacology for NASACORT ALLERGY 24 HOUR

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for NASACORT ALLERGY 24 HOUR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chattem Sanofi	NASACORT ALLERGY 24 HOUR	triamcinolone acetonide	SPRAY, METERED;NASAL	020468-002	Oct 11, 2013		OTC	Yes	Yes

Expired US Patents for NASACORT ALLERGY 24 HOUR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chattem Sanofi	NASACORT ALLERGY 24 HOUR	triamcinolone acetonide	SPRAY, METERED;NASAL	020468-002	Oct 11, 2013	5,976,573
Chattem Sanofi	NASACORT ALLERGY 24 HOUR	triamcinolone acetonide	SPRAY, METERED;NASAL	020468-002	Oct 11, 2013	6,143,329
Chattem Sanofi	NASACORT ALLERGY 24 HOUR	triamcinolone acetonide	SPRAY, METERED;NASAL	020468-002	Oct 11, 2013	7,977,045

International Patents for NASACORT ALLERGY 24 HOUR

See the table below for patents covering NASACORT ALLERGY 24 HOUR around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	318241
Slovakia	181698	AQUEOUS-BASED PHARMACEUTICAL COMPOSITION
Ukraine	68337	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ВОДНОЙ ОСНОВЕ;СПОСІБ ЛІКУВАННЯ РИНІТУ, ВОДНА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, СПОСІБ ЇЇ ПРИГОТУВАННЯ ТА ПРИСТРІЙ ДЛЯ РОЗПИЛЮВАННЯ (AQUEOUS PHARMACEUTICAL COMPOSITION)

NASACORT ALLERGY 24 HOUR Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Nasacort Allergy 24HR

Introduction

Nasacort Allergy 24HR, a nasal spray developed by Sanofi, has been a significant player in the over-the-counter (OTC) allergy treatment market since its transition from a prescription-only medication. Here, we delve into the market dynamics and financial trajectory of this product.

FDA Approval and Market Entry

In October 2013, the U.S. Food and Drug Administration (FDA) approved Nasacort Allergy 24HR for OTC use, marking a pivotal moment in its market entry. This approval was based on extensive clinical data, including 13 placebo-controlled efficacy studies and 43 clinical safety studies, as well as 16 years of post-marketing surveillance data[1][2].

Market Impact

The launch of Nasacort Allergy 24HR as an OTC product significantly expanded the treatment options for the over 60 million Americans suffering from seasonal and year-round nasal allergies. This move was seen as a strategic addition to Sanofi's consumer healthcare portfolio, which already included the Allegra family of products[1][2].

Unique Selling Points

Nasacort Allergy 24HR stands out as the only single active ingredient OTC medicine that relieves the full range of nasal allergy symptoms, including nasal congestion, for 24 hours with a single daily dose. It works differently from other OTC treatments by stopping more of the chemical responses that cause allergy symptoms, making it a gold standard treatment for hay fever and other upper respiratory allergies[1][2].

Packaging and Distribution

The product's packaging was designed to stand out in the retail market. Sanofi introduced an attractive wraparound paperboard pack featuring a thermoformed letter "N" for Nasacort, which helped the product gain visibility on store shelves. The product was available in various sizes, including 12- and 60-count spray varieties, and later a 120-spray version, catering to different consumer needs[4].

Financial Performance

The transition of Nasacort Allergy 24HR from a prescription to an OTC product was a financially strategic move for Sanofi. By making the product available without a prescription, Sanofi aimed to increase accessibility and sales volume. The average retail price of $13.99 for the 60-metered dose spray and $18.99 for the 120-metered dose spray positioned the product competitively in the market[4].

Revenue Growth

The OTC launch of Nasacort Allergy 24HR contributed significantly to Sanofi's consumer healthcare division revenue. The product's availability in mass merchandising stores, drug stores, and grocery stores ensured wide distribution and increased sales. While exact revenue figures for Nasacort Allergy 24HR are not publicly disclosed, the product's market presence and consumer demand suggest a positive financial trajectory.

Market Share

As the first and only medicine in its class available OTC at full prescription strength, Nasacort Allergy 24HR captured a substantial market share in the allergy treatment segment. This unique positioning helped Sanofi maintain a competitive edge in the consumer healthcare market[2].

Consumer Response and Satisfaction

Consumer response to Nasacort Allergy 24HR has been positive, with many users appreciating the convenience and effectiveness of the product. The product's ability to relieve a full range of nasal allergy symptoms without the need for a prescription has been a key factor in its success.

Quality of Life Impact

Nasacort Allergy 24HR has significantly improved the quality of life for many allergy sufferers. By providing 24-hour relief from symptoms such as sneezing, itchy nose, runny nose, and nasal congestion, the product has helped individuals manage their allergies more effectively, reducing disruptions to sleep, outdoor activities, and school performance[1][2].

Competitive Landscape

The allergy treatment market is highly competitive, with several OTC and prescription options available. However, Nasacort Allergy 24HR's unique status as the only single active ingredient OTC medicine in its class has helped it maintain a strong market position.

Differentiation

The product's differentiation from other OTC treatments, such as antihistamines and decongestants, lies in its ability to address the full range of nasal allergy symptoms through its corticosteroid action. This has made it a preferred choice for many consumers seeking comprehensive relief from allergy symptoms[1][2].

Future Outlook

The future outlook for Nasacort Allergy 24HR remains positive, driven by ongoing consumer demand for effective allergy treatments. Sanofi's continued investment in consumer healthcare and its expertise in prescription-to-OTC switches position the company well for future growth in this segment.

Market Trends

The increasing prevalence of allergies and the trend towards self-medication are expected to drive the demand for OTC allergy treatments. As consumers become more health-conscious and seek convenient, effective solutions, products like Nasacort Allergy 24HR are likely to continue gaining traction[2].

Key Takeaways

• FDA Approval: Nasacort Allergy 24HR was approved for OTC use in October 2013, based on extensive clinical data.
• Market Impact: The product expanded treatment options for over 60 million Americans suffering from nasal allergies.
• Unique Selling Points: It is the only single active ingredient OTC medicine relieving the full range of nasal allergy symptoms for 24 hours.
• Financial Performance: The product contributed significantly to Sanofi's consumer healthcare division revenue.
• Consumer Response: Positive consumer response due to its effectiveness and convenience.
• Competitive Landscape: Maintains a strong market position due to its unique status and differentiation.

FAQs

What is Nasacort Allergy 24HR?

Nasacort Allergy 24HR is an OTC nasal spray that relieves the full range of nasal allergy symptoms, including nasal congestion, for 24 hours with a single daily dose.

Who can use Nasacort Allergy 24HR?

Nasacort Allergy 24HR is approved for use in adults and children 2 years of age and older.

What makes Nasacort Allergy 24HR unique?

It is the only single active ingredient OTC medicine that relieves the full range of nasal allergy symptoms, including nasal congestion, for 24 hours.

How is Nasacort Allergy 24HR packaged?

The product is packaged in an attractive wraparound paperboard pack featuring a thermoformed letter "N" for Nasacort, available in various sizes.

What is the typical retail price of Nasacort Allergy 24HR?

The average retail price is $13.99 for the 60-metered dose spray and $18.99 for the 120-metered dose spray.

Sources

1. PR Newswire: FDA Approves Sanofi's Nasacort® Allergy 24HR for Over-the-Counter Use.
2. PR Newswire: Sanofi's Consumer Healthcare Division Chattem Announces Nasacort Allergy 24HR Nasal Spray Now Available Without a Prescription in the US.
3. Drug Patent Watch: Generic TRIAMCINOLONE ACETONIDE INN entry.
4. Healthcare Packaging: Sanofi's Nasacort® Allergy 24HR Booklet Pack with Thermoform Delivers Wow Factor.